Learn About Our Study
Newsroom

News & announcements

Updates on our clinical progress, corporate milestones, and the science behind mast-cell depletion.

Clinical · Featured

Calixis Announces Commencement of a Phase 2 Trial of Oral KIT Inhibitor THB335 in Chronic Spontaneous Urticaria

Randomized, double-blind, placebo-controlled study of once-daily THB335 in adults who remain symptomatic despite antihistamines, including patients who have failed or are intolerant to advanced therapies.

Cambridge, Mass. — September 1, 2026

Read the release

All updates

01 Sep 2026
Clinical

Calixis announces commencement of a Phase 2 trial of oral KIT inhibitor THB335 in CSU

Calixis has commenced THB335-201, a randomized, double-blind, placebo-controlled Phase 2 study of once-daily THB335 in adults with chronic spontaneous urticaria who remain symptomatic despite standard-of-care treatment.

Read more →
18 May 2026
Corporate

Calixis announces $45 million Series A financing from blue-chip life-science investors

The financing from Atlas Venture, OrbiMed, and Aditum Bio will advance Calixis's pipeline of oral mast-cell–targeted therapies, led by THB335 in chronic spontaneous urticaria.

Read more →
Stay informed

Get Calixis news in your inbox

Media and investors can reach us directly for the latest updates and announcements.

Contact media relations

Calixis's investigational compounds have not been approved by the U.S. Food and Drug Administration or any other regulatory authority. Their safety and efficacy have not been established. Forward-looking statements involve risks and uncertainties. This website is not medical advice.